Ishare Nq Biotch ETF (IBB) 260.81 $IBB Looking for

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ishare Nq Biotch ETF (IBB) 260.81 $IBB

Looking for Sunshine in Biotech's Gloomy First Quarter Performance
at The Street - Thu Mar 31, 3:01PM CDT
The Nasdaq Biotechnology Index (NBI) fell TK% in the first quarter. The last time the biotech index underperformed to this degree was in June 2002 when it lost 34%.
CPXX: 11.03 (+0.34), XBI: 51.66 (+1.49), AMGN: 149.93 (+0.45), PTCT: 6.44 (+0.35), IBB: 260.81 (+5.87)

iShares Nasdaq Biotechnology Index Rises 3.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Mar 31, 11:51AM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $254.88 to a high of $262.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $262.40 on volume of 901,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 260.81 (+5.87)

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 3.06% Gain
Comtex SmarTrend(R) - Thu Mar 31, 11:50AM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $254.88 to a high of $262.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $262.40 on volume of 901,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 260.81 (+5.87)

Initiating a Small Position in the Biotech ETF; Charts Look Promising
at The Street - Thu Mar 31, 10:38AM CDT
We haven't seen a recovery in biotechs yet, but it's a possibility. 
IBB: 260.81 (+5.87)

Jim Cramer -- Biotech Stocks' Window of Opportunity
at The Street - Fri Mar 25, 1:30PM CDT
Jim Cramer says that biotech stocks could have a window of opportunity to rally as Valeant rebounds and as politicians lay off the sector.
VRX: 26.30 (-0.77), IBB: 260.81 (+5.87)

Trader's Notebook: Biotech Has Momentum
at The Street - Wed Mar 23, 8:00AM CDT
Also, oil data surprise and E-mini bullishness wanes.
XBI: 51.66 (+1.49), IBB: 260.81 (+5.87)

Jim Cramer -- Bernie Sanders Dropout Could Rally Biotech Stocks
at The Street - Tue Mar 22, 11:57AM CDT
If Hillary Clinton can knock Bernie Sanders from the Democratic presidential race, it could spur a rally in the biotech sector, says Jim Cramer.
VRX: 26.30 (-0.77), AMGN: 149.93 (+0.45), IBB: 260.81 (+5.87)

Trader's Notebook: Reduced Volume Alert
at The Street - Tue Mar 22, 8:00AM CDT
Avoid over-trading at all costs.
IBB: 260.81 (+5.87)

After Yesterday's Rally of 1.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 21, 12:14PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $250.26 to a high of $257.66. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $255.50 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 260.81 (+5.87)

Better Buy: Intuitive Surgical, Inc. vs. Medtronic PLC
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 21, 8:01AM CDT
  The medical-device industry is expected to grow right along with average life spans and incomes among developed nations. Trying to ride this trend by investing in most drugmakers has been disastrous recently. The  Nasdaq Biotechnology Index ,...
ISRG: 601.05 (+2.77), MDT: 75.00 (-0.42), XPH: 40.24 (+0.40), IBB: 260.81 (+5.87), IHI: 122.48 (+0.15)

3 Biotech Stocks to Buy in March
Cheryl Swanson, Kristine Harjes, and Brian Feroldi, The Motley Fool - Motley Fool - Fri Mar 18, 3:39PM CDT
Looking for stocks to buy? It's time to get in some shots before the weather warms up. Flickr: Creative Commons March--as the saying goes--comes in like a lion and goes out like a lamb. And biotechs may be about to do the same, although it's...
PTLA: 20.40 (+0.20), IBB: 260.81 (+5.87), IONS: 40.50 (+1.87), REGN: 360.44 (+0.76)

3 Biotech Stocks to Buy on Sale
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Mar 18, 7:22AM CDT
Image Source TBIT via pixabay The broad S&P 500 has rallied over the last few weeks, and it has largely recovered from the beating that it took early in the year. The biotech sector, however, hasn't fared quite as well. Many biotech stocks...
AGN: 268.03 (-6.91), GERN: 2.92 (+0.05), PFE: 29.64 (-0.43), IBB: 260.81 (+5.87), CHRS: 21.23 (+1.98)

Rev's Forum: Be Careful About Being Too Negative Ahead of the Fed
at The Street - Wed Mar 16, 6:49AM CDT
The market still loves to love the Fed.
VRX: 26.30 (-0.77), IBB: 260.81 (+5.87)

The Trader Daily: Valeant's Crash Scatters Debris
at The Street - Wed Mar 16, 6:00AM CDT
Bad news was widespread amid biotech and related sectors.
PPH: 57.50 (-0.16), VRX: 26.30 (-0.77), XBI: 51.66 (+1.49), IBB: 260.81 (+5.87)

Why Exelixis' Stock Dropped 10% on Tuesday
George Budwell, The Motley Fool - Motley Fool - Wed Mar 09, 9:30AM CST
What: Shares of Exelixis , a small-cap biopharma focusing on the development of cancer treatments, fell by 10.42% yesterday on higher-than-normal volume. The good news is that this double-digit decline doesn't appear to be linked to a...
IBB: 260.81 (+5.87), EXEL: 4.00 (+0.10)

3 Reasons Jazz Pharmaceuticals Stock Could Rise in 2016
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 08, 12:20PM CST
Over the past 12 months, Jazz Pharmaceuticals stock has fallen along with the  Nasdaq Biotechnology ETF . Public outcry over rising prescription drug prices is largely to blame for the losses seen in the biotechnology index (and across the...
JAZZ: 130.55 (+6.52), IBB: 260.81 (+5.87)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.52% Rise
Comtex SmarTrend(R) - Mon Mar 07, 5:11PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.92 to a high of $272.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $269.79 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 260.81 (+5.87)

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.52% Yesterday
Comtex SmarTrend(R) - Mon Mar 07, 5:11PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.92 to a high of $272.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $269.79 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 260.81 (+5.87)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 4

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading

Top 5 Most Recently Viewed Articles

Gentherm's Q2 2025 Results Highlight Strong Performance & Future

Updated Category News Views 132

Gentherm's Financial Performance for Second Quarter 2025 Gentherm, a global innovator in thermal management technologies, reported outstanding financial outcomes for the second quarter of 2025. The company's revenue reached $375 million, underscoring its strength in the automotive sector, particularly within Climate and Comfort Solutions. Record Achievements and New...

Continue Reading
DEALMining Surpasses 6.8 Million Users with Exciting Rewards

Updated Category News Views 237

DEALMining Achieves Major User Milestone In a significant accomplishment, DEALMining has proudly announced that its user base has exceeded 6.8 million globally, marking its status as one of the fastest-growing compliant cloud mining platforms in the world. This impressive growth showcases DEALMining's successful outreach across more than 200 countries and regions, as the...

Continue Reading
Investigation Launched into Aehr Test Systems for Investors' Losses

Updated Category News Views 218

Investigation into Aehr Test Systems, Inc. Focused on Investor Protection The Law Offices of Frank R. Cruz are actively investigating Aehr Test Systems, Inc. (NASDAQ: AEHR) in light of significant concerns raised regarding the company’s adherence to federal securities laws. This investigation comes as a response to alarming financial disclosures made public by the...

Continue Reading
Vivoryon Therapeutics to Share Insights on 2024 Performance

Updated Category News Views 176

Vivoryon Therapeutics N.V. Set to Report Financial Outcomes Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is gearing up to unveil its financial results for the entirety of 2024, along with insights into its operational achievements. The highly anticipated announcement is scheduled for April 29, 2025, aiming to shed light on the company’s progress in...

Continue Reading
Navigating Economic Trends: Insights for Savvy Investors

Updated Category News Views 110

Understanding the Economic Climate In finance, a stable economy is often described as a "Goldilocks" economy, where conditions are ideal for investments to flourish. Lately, we have witnessed an economy that consistently surpasses expectations, putting worries about downturns to rest. The Search for Economic Balance Investors are keen to find that sweet spot where...

Continue Reading